U.S. ACELLULAR DERMAL MATRICES MARKET ANALYSIS

U.S. Acellular Dermal Matrices Market, By Origin (Human Dermis, Porcine Dermis, Bovine Dermis), By Application (Acute Wounds (Burns, Trauma, Cancers, Infections) Chronic Wounds (Diabetic Foot Ulcers, Venous Leg Ulcers, Pressure Ulcer, and Others), and Reconstruction Procedures (Abdominal Wall Procedures, Breast Procedures, Orthopedic Procedures, and Others), and By Place of Setting (Hospitals, Ambulatory Surgical Centers, and Office Based)

U.S. Acellular Dermal Matrices Market: Key Developments

In August 2021, Allosource, a company that manufactures fresh cartilage tissue for joint repair and skin allografts to heal severe burn, launched AlloMend Ultra-Thick Acellular Dermal Matrix (ADM). The product was designed for use in the repair or replacement of damaged or inadequate tissue required in demanding procedures, such as superior capsule reconstruction (SCR).
In March 2022, Smith&Nephew, the global medical technology business, announced the publication of a peer-reviewed study in the Advances in Wound Care Journal, providing results for Medicare patients with diabetic foot ulcers (DFUs) demonstrating that, in comparison to leading cellular therapies, GRAFIX Cryopreserved Placental Membrane lowered DFU recurrence rates in half.
On March 28, 2023, Bimini Health Tech, a global provider in the breast reconstruction and regenerative product and therapy announced that it acquired the exclusive rights of Acellular Dermal Matrix (“ADM”) technology for use in plastic and reconstructive surgery field. By acquiring the exclusive license for this technology, Bimini Health Tech will be able to leverage its existing infrastructure and expertise of the important technology to a wider patient population with an estimated U.S. market.